Comparison of C-Reactive Protein and Metabolic Syndrome as Cardiovascular Risk Factors in African-Americans and European-Americans

American Journal of Cardiology

Volumn 103, Issue 4, 2009, Pages 523-527

  Anuurad, Erdembileg ^a   Tracy, Russell P ^d   Pearson, Thomas A ^b   Beckett, Laurel ^c   Berglund, Lars ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

AFRICAN AMERICAN; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR;

ADULT; AFRICAN AMERICANS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; RISK FACTORS;

EID: 59049088744     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.10.016     Document Type: Article

References (22)

1. Anuurad E., Chiem A., Pearson T.A., and Berglund L. Metabolic syndrome components in African-Americans and European-American patients and its relation to coronary artery disease. Am J Cardiol 100 (2007) 830-834
2. Paultre F., Pearson T.A., Weil H.F., Tuck C.H., Myerson M., Rubin J., Francis C.K., Marx H.F., Philbin E.F., Reed R.G., and Berglund L. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
3. Anuurad E., Rubin J., Lu G., Pearson T.A., Holleran S., Ramakrishnan R., and Berglund L. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res 47 (2006) 2475-2481
4. McGowan M.W., Artiss J.D., Strandbergh D.R., and Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29 (1983) 538-542
5. Allain C.C., Poon L.S., Chan C.S., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
6. Warnick G.R., Benderson J., and Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28 (1982) 1379-1388
7. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
8. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
9. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
10. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
11. Adler A.I., Levy J.C., Matthews D.R., Stratton I.M., Hines G., and Holman R.R. Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 22 (2005) 306-311
12. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
13. Miller M., Mead L.A., Kwiterovich Jr. P.O., and Pearson T.A. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 65 (1990) 1-5
14. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
15. Toss H., Lindahl B., Siegbahn A., Wallentin L., and FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 96 (1997) 4204-4210
16. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
17. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
18. Ferrante Jr. A.W. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262 (2007) 408-414
19. Hotamisligil G.S., Budavari A., Murray D., and Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94 (1994) 1543-1549
20. Youd J.M., Rattigan S., and Clark M.G. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes 49 (2000) 1904-1909
21. Feingold K.R., and Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 41 suppl (1992) 97-101
22. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 36 (1993) 611-622